Purpose: In glioblastoma, EphB4 receptors, a member of the largest family of receptor tyrosine kinases, are overexpressed in both tumor cells and angiogenic blood vessels. The purpose of this study was to examine whether the EphB4-binding peptide TNYL-RAW labeled with both 64 Cu and near-infrared fluorescence dye Cy5.5 could be used as a molecular imaging agent for dual-modality positron emission tomography/computed tomography [PET/CT] and optical imaging of human glioblastoma in orthotopic brain tumor models. Materials and Methods: TNYL-RAW was conjugated to Cy5.5 and the radiometal chelator 1,4,7,10-tetraazadodecane-N,N′,N″,N‴-tetraacetic acid. The conjugate was then labeled with 64 Cu for in vitro binding and in vivo dual μPET/CT and optical imaging studies in nude mice implanted with EphB4-expressing U251 and EphB4-negative U87 human glioblastoma cells. Tumors and brains were removed at the end of the imaging sessions for immunohistochemical staining and fluorescence microscopic examinations. Results: μPET/CT and near-infrared optical imaging clearly showed specific uptake of the duallabeled TNYL-RAW peptide in both U251 and U87 tumors in the brains of the nude mice after intravenous injection of the peptide. In U251 tumors, the Cy5.5-labeled peptide colocalized with both tumor blood vessels and tumor cells; in U87 tumors, the tracer colocalized only with tumor blood vessels, not with tumor cells. Conclusions: Dual-labeled EphB4-specific peptide could be used as a noninvasive molecular imaging agent for PET/CT and optical imaging of glioblastoma owing to its ability to bind to both EphB4-expressing angiogenic blood vessels and EphB4-expressing tumor cells.
Introduction
G lioblastoma multiform (GBM) is the most malignant primary brain tumor. It exhibits rapid malignant progression and is extremely resistant to common multimodal therapies. GBM is characterized by the nature of extensive invasion into surrounding normal brain tissue, which often results in recurrence near the resection margin [1, 2] . The prognosis for individuals with GBM depends upon how early the tumor is detected and how quickly treatments begin. Early diagnosis and treatment often extend the quality and length of life for individuals suffering with GBM. Thus, there is a pressing need to develop new diagnostic imaging agents to detect GBM at an early stage and to evaluate its response to therapy.
Erythropoietin-producing human hepatocellular carcinoma (Eph) receptors are the largest family of vertebrate receptor tyrosine kinases. Eph signaling plays an important role in several normal developmental processes, such as cell migration, axon guidance, and angiogenesis and limb development [3] [4] [5] [6] [7] [8] [9] . Eph receptors have also been implicated in tumorigenesis, angiogenesis, invasion, and metastasis [10] [11] [12] [13] . Overexpression of the EphB4 receptor, an important member of the Eph receptor family, has been observed in numerous tumor types, including breast, prostate, bladder, lung, colon, ovarian, and gastric tumors [14] [15] [16] [17] [18] [19] [20] . In highgrade glioblastoma, EphB4 is expressed at high levels in both tumor cells and blood vessels [14] . Therefore, EphB4 is a promising target for noninvasive molecular imaging of glioblastoma.
Previously, we have reported use of the EphB4 receptor-specific TNYL-RAW peptide and TNYL-RAWconjugated polymeric micelles for molecular imaging of EphB4 expression in human cancer xenograft models [21, 22] . In the current study, we developed an EphB4-binding peptide labeled with both 64 Cu and near-infrared (NIR) fluorescence dye Cy5.5. We demonstrated that this duallabeled TNYL-RAW was able to target both EphB4-expressing angiogenic tumor blood vessels and EphB4-expressing tumor cells. Thus, dual-labeled EphB4 imaging agents could be used for dual positron emission tomography/computed tomography (PET/CT) and optical imaging of glioblastoma.
Materials and Methods

Reagents and Cell Lines
All amino acid derivatives and coupling reagents were purchased from Novabiochem (San Diego, CA), Bachem (Torrance, CA), and Chem-Impex International (Wood Dale, IL). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise specified. Synthesis of Cy5.5-TNYL-RAW and Cy5.5-TNYL-RAW-DOTA
were synthesized on solid phase (Fig. 1a) . Briefly, the Rink amide resin (0.05-0.1 g) was swollen and washed five times with 1.5 ml of dimethylformamide (DMF)/methylene chloride (CH 2 Cl 2 ). Fluorenylmethyloxycarbonyl (Fmoc) groups were removed by washing with 1.5 ml of 20 % piperidine in DMF two times for 20 min each. For coupling, threefold excesses of Fmoc-amino acids, diisopropylcarbodiimide, and 1-hydroxybenzotriazole were used in 3 ml of DMF/CH 2 Cl 2 . This procedure was then repeated once.
After the coupling and deprotection steps, resins were washed three times with 3 ml of DMF/CH 2 Cl 2 . After peptide chain elongation was complete, resins were washed three times with 3 ml of CH 2 Cl 2 and treated with trifluoroacetic acid/ triisopropylsilane/H 2 O (95:2.5:2.5, v/v/v) for 15 min each. The combined filtrates were left at room temperature for 1-2 h, and the volumes were then reduced in a vacuum. The resulting peptides Cy5.5-TNYL-RAW and Cy5.5-TNYL-RAWK were precipitated in ice-cold ethyl ether, collected by centrifugation, washed two times with ethyl ether, and centrifuged at 5,000 rpm for 10 min.
After they were dried, the peptides were purified by reversephase high-performance liquid chromatography (RP-HPLC) on an Agilent 1200 system (Vydac C-18, 10×250 mm, 10 μm; Agilent, Santa Clara, CA). A solution of 1,4,7,10-tetraazadodecane-N,N′, N″,N‴-tetraacetic acid (DOTA)-NHS (1 eq) and Cy5.5-TNYL-RAWK in DMF and N,N-diisopropylethylamine (10/1) was stirred at room temperature overnight. After the solvent was removed under vacuum, the residual was purified by RP-HPLC, eluted with a 0.01-M solution of NH 4 OAc in water and acetonitrile, and lyophilized to yield Cy5.5-TNYL-RAWK-DOTA. The scrambled peptide (scTNYL-RAW) and its corresponding labeled compounds Cy5.5-scTNYL-RAW and Cy5.5-scTNYL-RAWK-DOTA were similarly synthesized. The products were validated by analytical HPLC and electrospray ionization mass spectrometry (Agilent Technologies, Santa Clara, CA).
Immobilization of EphB4 Receptors to Sensor Chips
Stock solution (100 μg/ml) of EphB4/Fc (extracellular domain of human EphB4 fused to the carboxy terminal Fc region of human IgG1) in phosphate-buffered saline (PBS) was diluted to 25, 12.5, and 6.25 μg/ml with 10 mM sodium acetate buffer at pH 4.5 and immobilized to a CM5 sensor chip using the amine coupling reaction, following the manufacturer-provided procedures (GE Healthcare, Piscataway, NJ). Briefly, the surfaces of the chips in flow cell (FC)-1, FC-2, FC-3, and FC-4 were activated by exposing them to a mixture of 200 mMN-ethyl-N′-(dimethylaminopropyl)carbodiimide and 50 mMN-hydroxysuccinimide for 7 min. FC-1 was used as a reference surface and was directly deactivated by injection of 1 M ethanolamine at pH 8.5 for 7 min. FC-2, FC-3, and FC-4 were injected with 25, 12.5, and 6.25 μg/ml EphB4/Fc, respectively, followed by injection of 1 M ethanolamine to block the remaining activated ester groups on the surface. The chip was allowed to stabilize for at least 2 h in 10 mM HEPES buffer, pH 7.4, including 150 mM NaCl, 1 % BSA, 3 mM EDTA, and 0.005 % surfactant P20 (HBSEP) running buffer before the test analytes were injected.
Surface Plasmon Resonance Assay for Receptor Binding Affinity
Binding assays were performed at 25°C in HBSEP running buffer. The peptides were diluted in HBSEP buffer, filtered, degassed, and injected at concentrations between 1.6 and 800 nM at a flow rate of 30 μl per minute. The injection time of peptides into the HBSEP buffer was 4 min, followed by a 4-min dissociation period. The chips were regenerated using a 1-min pulse of 10 mM glycine (pH 2.2) after each binding circle. Each cycle consisted of a 1-min waiting period to allow monitoring of the baseline binding stability. For subtraction of bulk effects caused by changes in the buffer composition or nonspecific binding, double referencing was performed in surface plasmon resonance (SPR) binding studies. Thus, all samples analyzed were additionally injected onto an uncoated reference surface (FC-1). Samples of the running buffer were also injected onto the EphB4/Fc-coated flow cells. All sensorgrams were double-reference-subtracted from those obtained from the reference flow cell and those from bufferalone samples. Data were evaluated with BIAevaluation software (version 3.0, GE Healthcare) with application of a simple 1:1 binding mass transfer model. The sensorgrams obtained were fitted globally over the whole range of injected concentrations for both the association and dissociation phases. Equilibrium dissociation constants were then calculated from the rate constants (K d =K off /K on ).
Stable Transfection of Luciferase Gene into U251 Cells (U251-Luc)
U251 cells were seeded in six-well plates (5×10 5 cells per well) and incubated overnight at 37°C in a humidified incubator in an atmosphere of 5 % CO 2 24 h before the experiment. DMEM/F12 culture medium (2 ml), excluding fetal bovine serum, with 50 μl of Cignal™ Lenti Positive Control (luc) viral particles (Qiagen, Frederick, MD) and 8 μg/ml polybrene were added into the well after the previous complete DMEM/F12 culture medium was removed. The plates were gently swirled to mix the solution. Six hours later, the viral supernatant from the wells was removed, and the cells were reinfected with 2 ml of fresh supernatant (with 8 μg/ ml polybrene). The next day, viral supernatant was removed, and DMEM/F12 with 10 % fetal bovine serum was added into the cells.
The cells were incubated for 72 h and then subcultured into 100-mm dishes. Puromycin (Sigma, 1 μg/ml) was added into the cells to select the cells expressing luciferase. After 1 week, the luciferase activity of the selected positive cells was tested using the Xenogen IVIS-200 optical in vivo imaging system (Caliper Life Sciences, Hopkinton, MA).
Radiolabeling of Cy5.5-TNYL-RAWK-DOTA
64 CuCl 2 (74-148 MBq [2-4 mCi]) in 0.1 M sodium acetate (pH 5.2) was added to 10 μg of Cy5.5-TNYL-RAWK-DOTA in water. The reaction mixture was incubated at 70°C for 1 h. The progress of the reaction was monitored using a RP-HPLC system equipped with a NaCl crystal radiodetector. The reaction was terminated with the addition of ethylenediaminetetraacetic acid. The 64 Cu-labeled peptide was further purified, if necessary, by RP-HPLC on an Agilent 1100 system (4.6×250 mm, 10 mm; Vydac C-18) which was eluted with a linear gradient of 10-90 % acetonitrile in a 0.1 % aqueous trifluoroacetic acid solution over 35 min at a flow rate of 1.0 ml/min. Cy5.5-TNYL-RAWK-64 Cu-DOTA (retention time, 13.5 min) was collected in 1-to 2-ml fractions. The solvent was then removed, reconstituted in saline, and passed through a 0.22-mm filter for use in the animal experiments.
Radiochemical purity, defined as the ratio of the main product peak to all peaks, was determined by HPLC on an Agilent 1100 system (4.6×250 mm, 10 mm; Vydac C-18, with UV and radioactivity detectors). The column was eluted with a linear gradient of 10-90 % acetonitrile in a 0.1 % aqueous trifluoroacetic acid solution over 35 min at a flow rate of 1.0 ml/min.
Orthotopic Tumor Model
All animal work was carried out in accordance with the MD Anderson Institutional Animal Care and Use Committee guidelines. Male nude mice (8-10 weeks old; Charles River Laboratories, Houston, TX) were used for the imaging experiments. U87-Luc cells (1×10 6 ) or U251-Luc cells ( 3×10 6 ) were implanted into the brain of the nude mice (3 mm deep, 1 mm to the right and 2.5 mm behind the bregma) using a small animal stereotaxic device (David Kopf Instruments, Tujunga, CA).
Bioluminescence Imaging
On day 10 after tumor inoculation, the mice received a tail vein injection of D-luciferin (4 mg/kg). Tumor burden as measured by luciferase activity was assessed using the Xenogen IVIS-200 imaging system. The bioluminescence imaging signal generated in mice was quantified using Living Image V.2.11 software and IGOR image analysis software (V.4.02 A; WaveMetrics, Portland, OR). The region of interest (ROI) was manually selected, and the signal intensity was expressed in terms of the number of photons per second per square centimeter.
NIR Optical Imaging
Mice bearing U87-Luc tumors (n=12) or U251-Luc tumors (n=12) were imaged using the Xenogen IVIS-200 system at 1, 4, and 24 h after tail vein injection of 10 μg of Cy5.5-TNYL-RAWK-DOTA or scrambled peptide Cy5.5-scTNYL-RAWK-DOTA. The Cy5.5 fluorescence filter set (excitation 675 nm, bandwidth 30 nm; emission 695-770 nm) was applied. At the end of the last imaging session (24 h after injection), the mice were killed, various organ tissues were removed and weighed, and the fluorescence signal of the various tissues, including tumors, was analyzed using Living Cu-DOTA and with nonradiolabeled ("cold") Cy5.5-TNYL-RAWK-DOTA peptide at a dose of 50 μg/mouse. Images were acquired using an Inveon μPET/ CT system (Siemens, Washington, DC). Tumor-bearing mice were anesthetized with isoflurane (2 % in oxygen) and placed in prone position. The CT parameters were as follows: X-ray voltage, 80 kVp; anode current, 500 mA; and exposure time of each of the 360 rotational steps, 300-350 ms. Images were reconstructed using the two-dimensional ordered-subsets expectation maximization algorithm. PET and CT image fusion and image analysis were performed using Inveon Research Workplace (Siemens Preclinical Solutions). For tumor voxel intensity calculation, an irregular threedimensional ROI was manually drawn corresponding to PET images. A circular ROI was drawn on the normal brain area. A ROI was also drawn using a standard radiotracer solution (containing 1 % of the injection dose) placed beside the animals. The mean activities within the ROI of the tumor and normal brain were calculated in an Inveon Research Workplace workstation (Siemens).
Autoradiography
Mice brains containing tumors harvested at the end of the last μPET/CT imaging session were snap-frozen and cut into 10-μm sections. The sections were photographed and exposed on BAS-SR 2025 Fuji phosphorus films. The film was scanned with a FLA5100 Multifunctional Imaging System (Fujifilm Medical Systems USA, Stamford, CT). After the autoradiographic study, optical images of the sections were acquired using an Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE).
Hematoxylin and Eosin Staining and Immunohistochemical Analysis
After the μPET/CT studies were completed, the mice were killed, and their brains including implanted tumor were excised, snapfrozen, and cut into 4-μm sections. For NIR optical imaging study, U87-bearing mice were killed at 1, 4, and 24 h after peptide injection (n=4 for each time point). For immunohistochemical analysis, frozen U251-Luc and U87-Luc tumor sections were fixed in 4 % paraformaldehyde solution for 20 min at room temperature and washed with PBS three times. Tumor sections were blocked with 10 % goat serum for 30 min at room temperature, and the slides were then incubated with rabbit anti-human EphB4 antibody (1:100 dilution; U-200, Santa Cruz Biotechnology) and rat antimouse CD31 (1:50 dilution; Millipore) in PBS at 4°C overnight. After incubation with the primary antibody, slides were washed with PBS three times and incubated with secondary goat anti-rabbit antibody conjugated with Alexa Fluor 488 (1:500 dilution; Invitrogen, Grand Island, NY) and donkey anti-rat antibody conjugated with Alexa Fluor 594 (1:500 dilution, Invitrogen). Slides were washed again in PBS and counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Frozen slides were sent to the core histology facility at MD Anderson for hematoxylin and eosin (H&E) staining. Photomicrographs were obtained using a Zeiss Axiovert Z.1 fluorescence microscope (Zeiss, Germany).
Statistical Analysis
Student t tests were used to analyze biodistribution data. P values G0.05 were considered statistically significant calculated by Microsoft Excel software.
Results
Synthesis and Radiolabeling of Cy5.5-TNYL-RAWK-DOTA
Peptide synthesis and introduction of Cy5.5 were carried out on solid phase (Fig. 1a) 4 ) was calculated to be 3,175.3224; the actual measurement was 3,175.3350. Radiochemical purity, defined as the ratio of the main product peak to all peaks, was determined by HPLC to be 995 % (Fig. 1b) . The specific activity of Cy5.5-TNYL-RAWK- 64 Cu-DOTA used in the in vitro and in vivo experiments was typically 7.4-14.8 MBq/nmol (0.2-0.4 Ci/ μmol) at the end of synthesis.
Binding Affinity of Cy5.5-TNYL-RAW and Cy5.5-TNYL-RAWK-DOTA Figure 2 shows representative sensorgrams obtained from SPR analyses of DOTA-TNYL-RAW, Cy5.5-TNYL-RAW, Cy5.5-TNYL-RAWK-DOTA, and scrambled peptide Cy5.5-scTNYL-RAW, with fitting curves obtained using a global 1:1 mass transfer model. The corresponding binding kinetics and affinity data are summarized in Table 1 . TNYL-RAW had a K d of 3.06 nM. Conjugation of Cy5.5 to the Nterminus or Cy5.5 to the N-terminus and DOTA to the Cterminus of the peptide did not significantly affect the K d value of the parent TNYL-RAW peptide. Conjugation of DOTA to the N-terminus, on the other hand, increased the K d value by a factor of 7.6 (Table 1) .
Optical Imaging of U251-Luc and U87-Luc Tumors in the Brain
Ten days after inoculation of U87-Luc or U251-Luc cells into the brain of nude mice, strong luciferase activity was detected (Fig. 3a) , indicating successful tumor intake after orthotopic tumor cell implantation. Figure 3b shows Cy5.5 fluorescence optical images of U87-Luc and U251-Luc tumors in the mouse brain 24 h after tail vein injection of Cy5.5-TNYL-RAWK-DOTA. Both U87-Luc and U251-Luc tumors were clearly visualized. To confirm the specific tumor uptake of Cy5.5-TNYL-RAWK-DOTA, NIR fluorescence imaging of Cy5.5-TNYL-RAWK-DOTA was compared with that of Cy5.5-conjugated scrambled TNYL-RAW peptide (Cy5.5-scTNYL-RAWK-DOTA) in mice bearing U87-Luc tumors. At 1, 4, and 24 h after intravenous injection, brain tumor uptake of Cy5.5-TNYL-RAWK-DOTA, but not Cy5.5-scTNYL-RAWK-DOTA, was clearly shown (Fig. 4) . Figure 5a compares the biodistribution of Cy5.5-TNYL-RAWK-DOTA with that of Cy5.5-scTNYL-RAWK-DOTA in ex vivo analysis of dissected tissues from mice bearing U87-Luc tumors at different time points. For both compounds, high fluorescence activity was found in the liver, kidney, stomach, and intestine. At each time interval (1, 4 , and 24 h), the uptake of Cy5.5-TNYL-RAWK-DOTA in U87-Luc tumors was significantly higher than that of Cy5.5-scTNYL-RAW-DOTA (PG0.05) (Fig. 5b) . Figure 6a shows μPET/CT images of both coronal and transverse slices of mouse brains containing U87-Luc tumors. Tumors were clearly visualized at 1 and 24 h after tail vein Cu-DOTA. Fig. 6b compares μPET/CT images obtained in the presence and absence of an excess dose of cold Cy5.5-TNYL-RAWK-DOTA at 1 and 24 h after radiotracer injection in U251-Luc tumor-bearing mice. The U251-Luc tumors were clearly visualized at both time points in the absence of the cold peptide, but tumors were barely discernible in the mice injected with the cold peptide. Coadministration of cold Cy5.5-TNYL-RAWK-DOTA caused a 57 % reduction in the ratio of Cy5.5-TNYL-RAWK- 64 Cu-DOTA accumulation in the U251-Luc tumors compared with normal brain tissue, on the basis of tumor voxel intensity calculated from the μPET/CT images (PG0.05, Fig. 6c ).
Ex vivo Analysis of the Fluorescence Signal Intensities of Dissected Tissues
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Autoradiography and H&E Histology
Intracranial distribution of Cy5.5-TNYL-RAWK-64 Cu-DOTA was visible in both autoradiographic images and fluorescence optical images of sections of mouse brain with U251-Luc tumor (Fig. 6d) . Nuclear and optical signals were high in the U251-Luc brain tumors, and signals from radioactivity colocalized with signals from fluorescence. Fig. 6d also confirms typical tumor morphology in photomicrographs of H&E-stained tissue sections from areas with high nuclear and optical signal intensity.
Immunofluorescence
In Fig. 7 , immunofluorescence shows expression of EphB4, the binding site of the Cy5.5-labeled TNYL-RAW peptide, on mouse brain sections containing implanted U251-Luc and U87-Luc tumors. In U251-Luc tumors, EphB4 (green) was expressed in both tumor cells and tumor-associated blood vessels (red CD31 staining). Cy5.5-TNYL-RAWK-64 Cu-DOTA also bound to both tumor cells and tumor microvessels. However, in U87 tumors, EphB4 expression was detected only in tumor microvessels, not in tumor cells, and Cy5.5-TNYL-RAWK-64 Cu-DOTA bound only to the tumor microvessels (Fig. 7) .
Discussion
Various imaging techniques are available for differential diagnosis and evaluation of glioblastomas as well as for monitoring response to treatment. PET imaging has a high detection sensitivity, which makes it especially suitable for tracking radiotracers used in noninvasive in vivo molecular imaging. However, PET imaging does not provide sufficient resolution. Optical imaging (near-infrared fluorescence, bioluminescence, photoacoustic imaging, etc.) is an emerging molecular imaging modality that offers high sensitivity, high spatial resolution (e.g., photoacoustic imaging), low cost, and real-time data acquisition and does not use ionization radiation [23] [24] [25] [26] [27] [28] [29] . Furthermore, the fluorescent signal from the imaging probes permits ex vivo analysis of excised tissues for validation of their binding to the molecular targets in vivo. Because of limited penetration depth, near-infrared fluorescence imaging is better applied in intraoperative setting to facilitate surgical resection of glioma because it defines tumor margin better than the currently used imaging modalities such as PET and MRI [30] . In a recent study, Stummer et al. [31] demonstrated in a clinical trial that glioblastomas contrast-enhanced with 5-aminolevulinic acid, which is a natural precursor of hemoglobin that elicits synthesis and accumulation of fluorescent porphyrins in glioblastoma tissue, were completely resected in 90 of 139 patients (65 %), whereas tumors enhanced with white light were completely resected in only 47 (36 %) of 131 patients. Using enhanced fluorescent contrast agents facilitated more complete resection of the glioblastomas, which led to 6-month improved progression-free survival in patients with malignant glioblastoma [31] . These encouraging results clearly invite for further improvement in outcome through the use of highly sensitive, highly specific NIR fluorescence imaging probes.
In the current study, we developed dual-labeled EphB4-specific TNYL-RAW peptides for visualization of glioblastomas with μPET/CT and NIR fluorescence imaging in an orthotopic mouse model. SPR analysis showed that the K d values of Cy5.5-TNYL-RAW and Cy5.5-TNYL-RAWK-DOTA were~1 nM, in the same order of magnitude as the K d values of the parent TNYL-RAW peptide (3.07 nM). This high binding affinity of the dual-labeled EphB4-specific peptide to the EphB4 receptor in vitro makes it suitable for in vivo molecular imaging applications.
We found that 64 Cu-labeled Cy5.5-TNYL-RAW-DOTA peptide was taken up in both U251-Luc and U87-Luc tumors in the brain of nude mice and that fluorescent signal intensity reduced 57 % by in U251-Luc tumors by coinjection of a large excess of cold Cy5.5-TNYL-RAWK-DOTA peptide along with Cy5.5-TNYL-RAWK-64 Cu-DOTA. In addition, the scrambled peptide had insignificant uptake in the U87-Luc tumors. Taken together, these data suggest that tumor uptake of Cy5.5-TNYL-RAWK- 64 Cu-DOTA in brain tumor xenografts is mediated by EphB4 receptors.
The tumor-associated blood vessels in the orthotopic mice models of human glioma also express EphB4. According to the gene sequence alignment, human and mouse EphB4 receptor extracellular domains share approximately 88 % homology. Radiolabeled TNYL-RAW has been shown to bind to EphB4-expressing tumor cells of both mouse and human origins [21] . Interestingly, in the U251 model, we found that Cy5.5-labeled peptides bound to tumor cells and tumor-associated blood vessels, both of which express EphB4. In contrast, in the U87 model, Cy5.5-labeled peptides bound only to tumor-associated vessels, which expressed EphB4, but not to tumor cells, which did not express EphB4 (Fig. 7) . These findings suggested that EphB4-binding peptides could be useful for noninvasive imaging of both EphB4-expressing angiogenic blood vessels and tumor cells.
Conclusions
In this study, we found that a TNYL-RAW peptide labeled with 64 Cu and Cy5.5 was an effective agent for μPET/CT imaging and NIR optical imaging in orthotopic glioblastoma mouse models. We further showed that the dual-labeled imaging probe is capable of binding to both EphB4-expressing angiogenic blood vessels and tumor cells. Mice bearing a U251-Luc or U87-Luc tumor were injected intravenously with Cy5.5-TNYL-RAWK-64 Cu-DOTA peptides. Signal from Cy5.5 is pseudocolored purple. EphB4 (green) was stained with rabbit anti-human EphB4 antibody and Alexa Fluor 488-conjugated goat anti-rabbit immunoglobulin. CD31 (red), which is the marker of the endothelial cells of tumor-associated blood vessels, was stained with rat anti-mouse CD31 antibody and Alexa Fluor 594-conjugated donkey anti-rat antibody. Cell nuclei were counterstained with DAPI (blue). Bar=40 μm.
Specifically, in U87-Luc tumors, the dual-labeled peptide bound only to CD31-and EphB4-expressing tumor blood vessels, not to tumor cells (which did not express EphB4); however, in the U251-Luc tumors, the dual-labeled peptide bound to both EphB4-expressing angiogenic blood vessels and EphB4-expressing tumor cells. Thus, dual-labeled EphB4-specific peptide may be potentially useful as a molecular imaging agent for PET/CT detection of glioblastoma, followed by near-infrared fluorescence image-guided surgery.
